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Abstract 
Following a single blind, cross-over and non-randomized design we investigated the effect of 
7-day use of chlorhexidine (CHX) mouthwash on the salivary microbiome as well as several 
saliva and plasma biomarkers in 36 healthy individuals. They rinsed their mouth (for 1 min) 
twice a day for seven days with a placebo mouthwash and then repeated this protocol with 
CHX mouthwash for a further seven days. Saliva and blood samples were taken at the end of 
each treatment to analyse the abundance and diversity of oral bacteria, and pH, lactate, 
glucose, nitrate and nitrite concentrations. CHX significantly increased the abundance of 
Firmicutes and Proteobacteria, and reduced the content of Bacteroidetes, TM7, SR1 and 
Fusobacteria. This shift was associated with a significant decrease in saliva pH and buffering 
capacity, accompanied by an increase in saliva lactate and glucose levels. Lower saliva and 
plasma nitrite concentrations were found after using CHX, followed by a trend of increased 
systolic blood pressure. Overall, this study demonstrates that mouthwash containing CHX is 
associated with a major shift in the salivary microbiome, leading to more acidic conditions and 
lower nitrite availability in healthy individuals. 
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Introduction 
Chlorhexidine (CHX) has been commonly used in dental practice as antiseptic agent since 
1970, due to its long-lasting antibacterial activity with a broad-spectrum of action1. Since then, 
many clinical trials have shown effective results of CHX for the clinical management of dental 
plaque and gingival inflammation and bleeding2-4. This is supported by other studies performed 
in vitro conditions, reporting positive results of CHX in reducing the proliferation of bacterial 
species associated with periodontal disease, such as Enterobacteria, Porphyromonas 
gingivalis, Fusobacterium nucleatum, as well as different species of Actinomyces and 
Streptococcus, including Streptococcus mutans, which is considered the main etiological 
agent of dental caries4,5. Other studies have also reported that the use of CHX was effective 
in the treatment of halitosis, especially in reducing the levels of halitosis-related bacteria 
colonising the dorsal surface of the tongue6.  
The anti-microbial activity of CHX however, has been extensively studied using in vitro culture  
methods, which limit the identification and cultivation of all microorganisms in the 
environment4. To the best of our knowledge, only one recent study has investigated the effect 
of CHX mouthwash on mixed bacterial communities (microbiome) of the tongue using new 
genome sequencing techniques, such as 16S rRNA7. The study found differences in over 10 
different species colonizing the tongue, and a lower microbial diversity after using CHX for a 
week, but did not analyse other parameters related to oral health such as pH, acid production 
or buffering capacity7. Additionally, we and others have recently shown that the use of CHX in 
healthy subjects can attenuate the nitrate-reducing activity of oral bacteria by at least 80%8-11. 
This in turn leads to lower nitrite availability and an increase of blood pressure, suggesting 
that the oral microbiome can regulate cardiovascular health in healthy individuals and 
hypertensive patients8,11.  
CHX is widely available over the counter and is used in healthy patients, but it is unknown 
whether it promotes a healthy oral microbiome, or it may cause a shift to a microbiome 
associated with disease. Thus, the main aim of this study was to investigate the effects of 7-
4 
 
day use of CHX mouthwash on the oral microbiome of healthy participants, and its impact on 
several saliva markers such as pH, buffering capacity, lactate and glucose levels. We also 
investigated saliva and plasma concentrations of nitrate and nitrite with respect to blood 
pressure changes.  
Results  
Thirty six healthy participants successfully completed this study (Table 1). 
-Table 1 here- 
Oral microbiome analysis 
Changes in the abundance of phyla are shown in Figure 1A and 1B. The ratio between the 
main two phyla (Firmicutes/Bacteroidetes) is shown in Figure 1C. CHX increased the 
abundance Firmicutes (FDR <0.001) and Proteobacteria (FDR <0.001) and lowered the 
abundance of Bacteroidetes (FDR <0.001), TM7 (FDR <0.001), SR1 (FDR <0.001) and 
Fusobacteria (FDR=0.043).  
Changes at genus level are presented in Figures 1D and 1E. Within the phylum Firmicutes, 
the genus Bulleidia (FDR=0.023) and Streptococcus (FDR=0.020) were increased after using 
CHX, while 4 other genera decreased: Clostridium (FDR=0.035), Megasphera (FDR=0.001), 
Catonella (FDR <0.001) and Lachnoanaerobaculum (FDR <0.001). Regarding Proteobacteria, 
CHX led to an increase in Neisseria (FDR=0.004), Hylemonella (FDR=0.004) and Eikenella 
(FDR <0.001) as well as a reduction in Campylobacter (FDR=0.035). Changes in 
Bactoroidetes were led by an increase of Capnocytophaga (FDR <0.001) and a decrease in 
Prevotella (FDR <0.001). A significant reduction in non-assigned genera was found after CHX 
treatment (FDR=0.004).  
Figures 1F and 1G show the main changes at family level. Three families within the phylum 
Firmicutes increased after using CHX: Erysipelotrichaceae (FDR=0.019), Streptococcaceae 
(FDR=0.012) and Carnobacteriaceae (FDR=0.012), whilst three other families decreased: 
Clostridiaceae (FDR=0.027), Mogibacteriaceae (FDR <0.001) and Lachnospiraceae 
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(FDR=0.005). The increase of the phylum Proteobacteria after CHX treatment was attributable 
to an increase in the abundance of 3 families: Neisseriaceae (FDR=0.003), 
Comamonadaceae (FDR=0.004) and Enterobacteriaceae (FDR=0.005). This was also 
accompanied by a decrease of the family Campylobacteraceae (FDR=0.027). On the other 
hand, lower abundance of the phylum Bacteroidetes was attributable to lower abundance of 2 
families: Prevotellaceae (FDR <0.001) and Paraprevotellaceae (FDR <0.001) and an increase 
of the family Flavobacteriaceae (FDR <0.001). Within the phylum Fusobacteria, the family 
Fusobacteriaceae (FDR=0.003) showed the greatest reduction following CHX treatment, 
whilst in the phylum TM7, F16 (FDR=0.004) levels showed the greatest reduction. Finally, 
although the abundance of Actinobacteria did not significantly change after using CHX 
compared to placebo at phylum level, some families such as Actinomycetaceae (FDR=0.007) 
and Corynebacteriaceae (FDR=0.001) belonging to this phyla were significantly reduced by 
CHX. Finally, regarding alpha diversity, a significant decrease in the Shannon index was found 
after using CHX compared to placebo (FDR=0.001) (Figure 2A). Beta diversity was also 
significantly affected by CHX as shown by greater dissimilarity of the Bray-Curtis plot 
compared to placebo (Figure 2B).  
-Figures 1A, 1B, 1C, 1D, 1E, 1F and 1G here- 
-Figures 2A and 2B here- 
 
Saliva and plasma markers 
Salivary pH and buffering capacity were significantly reduced after using CHX compared to 
placebo (Figure 3A and 3B). This was accompanied by a significant increase of salivary lactate 
and glucose (Figure 3C and 3D). CHX also led to lower oral nitrate-reducing capacity (Figure 
3E), which in turn, led to lower saliva and plasma nitrite availability (Figure 3F and 3H) and 
increased salivary nitrate concentration (Figure 3G).  
-Figures 3A, 3B, 3C, 3D, 3E, 3F, 3G, 3H and 3I here- 
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Correlations  
We found several moderate correlations between the abundance of oral bacteria and salivary 
biomarkers after using the placebo and CHX mouthwash (Figure 4). In the placebo condition, 
greater abundance of Proteobacteria was negatively correlated with greater ability to form 
nitrite in the mouth (oral nitrate-reducing activity) (Figure 4A). Furthermore, greater abundance 
of Proteobacteria was associated with lower diastolic blood pressure (Figure 4D). Plasma 
nitrite was negatively correlated with Bacteroidetes (Figure 4B) and positively correlated with 
Actinobacteria (Figure 4E). Greater abundance of SR1 was also correlated with higher pH 
salivary values (Figure 4C).  
All these correlations changed after using CHX. We only found a positive correlation between 
Fusobacteria and saliva glucose (Figure 4F), and a negative correlation between 
Actinobacteria and Proteobacteria and lactate and nitrite in saliva (Figure 4G and Figure 4H), 
respectively.  
-Figures 4A, 4B, 4C, 4D, 4E, 4F, 4G, 4H here - 
 
Blood pressure 
When CHX was administered systolic blood pressure increased although it was not statistically 
significant  (Figure 5A).  
-Figure 5 A and B here- 
 
Discussion 
This study showed that CHX mouthwash significantly changed the oral microbiome towards 
greater abundance of Firmicutes and Proteobacteria species, with lower abundance of 
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Bacteroidetes, TM7, SR1 and Fusobacteria. These changes were associated with an increase 
in oral acidic conditions, represented by higher salivary lactate concentrations and lower 
salivary pH and buffering capacity. Additionally, CHX disrupted the ability of oral bacteria to 
reduce nitrate into nitrite, which may support our finding of lower circulatory nitrite 
bioavailability. 
To the best of our knowledge, this is the first study showing the impact of 7-day use of CHX 
on the oral microbiome. A large body of literature suggests that mouthwashes with CHX are 
effective in reducing dental plaque accumulation, gingival inflammation and bleeding2-4. 
However, the view about oral bacteria and oral health has changed substantially over the last 
few years12. Current approaches, using genome sequencing to identify and quantify the 
microorganisms in dental biofilms, have revealed a much more complex ecosystem than 
previously appreciated13. Results from this study showed that CHX led to an increase in the 
abundance of some genera such as Neisseria, Streptococcus and Granulicatella, and lowered 
the abundance of Actinomyces, but did not affect the abundance of Veillonella. However, it 
remains difficult to determine whether these microbial changes suggest a shift towards a 
healthy oral environment, or promote oral disease, as both increases and decreases in the 
bacteria associated with caries and periodontal disease have been seen14. Consequently, 
additional studies are required to investigate bacterial communities during different disease 
states, with and without CHX. Nevertheless, in the current study, we were able to associate 
genome sequencing measurements with other general markers of oral health, which allowed 
us to analyse more in detail the impact of mouthwash containing CHX on oral and systemic 
health.  
Lower microbial diversity as represented by the Shannon’s index was found after using CHX. 
This result is in agreement with another recent study showing lower diversity of bacteria 
colonizing the tongue7. These findings are relevant from a dental viewpoint since lower 
diversity of oral bacteria has been related to greater risk of oral diseases13. This may reflect 
the ecological pressure of lowered environmental pH. Healthy biofilms are associated with an 
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active balance between slow rates of acid production and compensatory alkali generation, 
resulting in an environment with a broadly neutral pH12. Surprisingly, the effect of CHX in 
salivary pH has only been investigated acutely in both in vivo15 and in vitro conditions16, but, 
no previous study has analysed the impact of this antibacterial compound over a period of 
days in healthy individuals. Our results showing lower saliva pH after using CHX are relevant, 
since decreased pH in saliva is associated with demineralization of tooth enamel and risk of 
caries, tooth loss and other dental problems17. Oral pH may differ between different oral 
conditions: whilst saliva pH is more alkaline in chronic gingivitis, it tends to be more acidic in 
chronic periodontitis18. Thus, in terms of salivary pH, CHX could therefore be more useful for 
managing gingivitis than periodontitis.  
Saliva’s composition is another factor to pay attention when analysing the antimicrobial 
effectiveness of CHX. Several in vitro studies have indicated that saliva has a neutralizing 
effect on CHX19-21. Since CHX is a strongly cationic molecule it can react with anionic 
chemicals, resulting in inactivation of antimicrobial activity. We did not analyse the 
antimicrobial interaction between saliva and CHX in this study, but, we investigated the effect 
of CHX in several saliva markers. We found that CHX increased the acidic conditions of saliva 
by increasing lactate concentration and reducing its buffering capacity and pH. These changes 
are commonly associated with greater risk of oral disease22. Regarding bacteria, we found a 
negative correlation between the phylum Actinobacteria and saliva lactate concentration. This 
phylum comprises a large variety of Gram-positive bacteria and is known for its high 
production of bioactive compounds, including those with antimicrobial activity such as 
lantibiotics23. For instance, Nisin is one of the best known antibiotics for its highly effective 
bactericidal activity against most lactic acid bacteria24. Another important bacterial change 
associated with CHX administration was an increase of the major phyla Firmicutes, mainly 
comprised of an increase of the genus Streptococcus. This genus contains several families of 
lactic acid bacteria that are able to produce large quantities of acid in the mouth25. On the 
other hand, we also found a significant decrease in the abundance of Bacteroidetes after using 
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CHX. This was the second most abundant phyla in the oral cavity and some genera from this 
phyla such as Veillonella has been shown to be important in maintaining the acid/base 
conditions in the mouth26. Overall, these findings indicate that CHX promotes acidification of 
saliva by changing the ratio abundance of different families of bacteria that are essential to 
maintain the acid/base conditions in the mouth of healthy people.  
Oral nitrite synthesis is another factor to take into account, with regards to the acid/base 
conditions of the oral cavity27. Nitrite is a nitrogen compound that forms naturally in the mouth 
by the action of oral bacteria that can use exogenous (diet) or endogenous (nitric oxide 
synthesis) nitrate sources28. Species within the genus Veillonella and Actinomyces have been 
suggested to lead this reaction in the oral cavity29. Importantly, CHX had a detrimental effect 
lowering the abundance of bacteria from these groups and reducing nitrite availability. Thus, 
the detrimental effect of CHX on oral nitrite synthesis is another key point requiring further 
attention by dental professionals, since nitrite has been shown to have an inhibitory effect in 
the growth of periodontal bacteria which can also help to reduce the acid production from 
these strains27,30.  
On the other hand, nitrite synthesis in the mouth has been shown to play a key role in 
cardiovascular control by enhancing circulatory nitrite availability. The vasodilatory effects of 
nitrite are well described by previous studies using intra-arterial infusions or dietary 
supplements with this anion31,32. Some recent studies, but not all9,33, have also found that the 
use of CHX mouthwash from 3 to 7 days led to higher blood pressure in healthy8 and 
hypertensive individuals34. Participants from these studies had higher values of blood pressure 
compared to participants in our current study. In agreement with our results, Sundqvist et al33 
did not show a raise in blood pressure in a young and healthy group of females after using 
CHX for three days. Additional studies are required to improve our understanding about the 
hypertensive effect of CHX in males and females with different resting blood pressure levels 
and physiological status, especially, after new evidence has shown that CHX raised the 
mortality rate in hospitalized patients35. Overall, current studies seem to indicate that the use 
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of CHX mouthwash leads to an increase of blood pressure, and this may be more accentuated 
in people with high blood pressure levels8,9,11,33.  
This study has some limitations. For instance, it would be interesting to analyse the effect of 
CHX in patients with different oral health conditions such as gingivitis or periodontitis. We 
assessed the oral health status of participants using a medical questionnaire, but it would be 
useful to undertake a full oral and dental examination, to analyse more in detail the concurrent 
effect of CHX on markers of periodontal health. Treatments were not randomized in this study 
due to the lack of available data indicating the time needed for the full recovery of the oral 
microbiome after one-week use of CHX. Consequently, there was not a wash out period 
between treatments. Furthermore, we analysed the microbiome in saliva as it provides an 
average of the oral microbiome, but bacterial communities can significantly differ among sites 
in distinct microbial niches in the oral cavity, therefore where the effects of CHX may also 
differ.   
In conclusion this study indicates that a 7-day use of CHX mouthwash has a significant impact 
on the oral microbiome, as well as shift to an acidic environment, favourable for increased 
dental caries, and a reduction of the amount of oral nitrate-reducing bacteria, which contribute 
to cardiovascular health. Thus, these findings add to the growing body of evidence that the 
applications of CHX mouthwash should be more carefully considered, and that CHX could 
have detrimental effects on the healthy microbiome, and in turn cardiovascular health, 
requiring further investigation. 
Methods   
This study was approved by the Ethics Committee of the Faculty of Health & Human Sciences 
(University of Plymouth) and was carried out in accordance with the Code of Ethics of the 
World Medical Association (Declaration of Helsinki) for experiments involving human subjects. 
All the participants provided written consent to participate in this study. This study was also 
registered on http://www.clinicaltrials.gov (NCT03871777; date of registration: 12/03/2019). 
11 
 
Parts of the data presented herein were extracted from a study that examined the dietary 
consumption of nitrate in healthy vegetarian and omnivore subjects and the impact of inhibiting 
the nitrate-reducing activity of oral bacteria using CHX mouthwash in blood pressure9.    
Main protocol 
Following a single blinded, non-randomized, cross over design participants visited the 
laboratory twice. Before the first trial, each participant received 14 tubes containing 10 mL 
placebo mouthwash (ultrapure unflavoured water), with which they rinsed their mouth for 1 
min, twice a day for 7 days taking the final tube the night before the trial. Individuals were 
excluded from this study if they were smokers, using mouthwash or tongue scrapes, suffering 
from gingivitis or periodontitis, or exhibited a medical condition (e.g hypertension, diabetes). 
For standardisation, they were also given the same toothpaste to use throughout the duration 
of the study. Participants visited the laboratory on the eighth day between 8 and 10 am, having 
fasted overnight. Additionally, at least 24h prior to their visit, they were sent written instructions 
via email to avoid drinks containing caffeine, such as tea or coffee, before the test and to 
refrain from strenuous exercise. Basic anthropometrical (weight and height) and physiological 
(blood pressure) parameters were measured before the collection of a plasma sample and a 
non-stimulated salivary sample (3 mL) as previously indicated9. Then, the oral nitrate-reducing 
capacity was also measured. At the end of the visit, the participant was given a further one-
week supply of antibacterial mouthwash containing 0.2% CHX (Corsodyl Mint, 
GlaxoSmithKline, UK), instructed to use it as per the previous mouthwash (1 min, twice a day) 
and requested to return to the laboratory in 7 days to repeat all measurements in the same 
order. 
Bacterial analysis  
Saliva pellets were extracted and frozen at −80 °C in a single sterile tube prior to metagenomic 
sequencing of the oral microbiome. DNA extraction of saliva and sequencing was performed 
as previously described at the Systems Biology Centre in Plymouth University (UK)9.  
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Saliva lactate, glucose and pH   
Saliva concentrations of lactate and glucose were measured using a biochemistry analyser 
(YSI 2300 Stat Plus, YSI Life Sciences, USA). Salivary pH was measured using a single 
electrode digital pH meter (Lutron Electronic Enterprise Co Ltd., Model PH-208, Taiwan) that 
was calibrated following the manufacturer's instructions. 
Saliva buffering capacity 
250 µL of saliva was mixed with 750 µL of HCl (0.0033 m/L) and shaken for 20 min. Then, 
salivary pH was measured using a single electrode digital pH meter (Lutron Electronic 
Enterprise Co Ltd., Model PH-208, Taiwan).  
Saliva and plasma concentration of nitrate and nitrite  
Whole blood was collected into lithium-heparin tubes (BD Vacutainer®, Becton Dickinson, 
Plymouth, UK) and rapidly centrifuged (4,000 rpm, 4 °C, 10 min). The plasma was then 
separated, and frozen at −80 °C until further analyses of nitrate and nitrite. Both anions were 
measured in saliva and plasma using ozone-based chemiluminescence as previously 
described36. 
Oral-nitrate reducing capacity  
Participants were instructed to hold 10 mL of water containing sodium nitrate (80 μmol) in their 
mouth for 5 min. The mouth rinse was collected into a sterile Falcon tube and centrifuged 
(4,000 rpm, 4 °C) for 10 min. The supernatant was collected and stored at −80 °C before 
measurement of absolute nitrite concentration as indicated above. 
Blood pressure measurement 
Participants rested in a supine position for 30 min, before three successive readings were 
taken (four if variation in systolic or diastolic blood pressure of >4 mmHg was found), using an 
oscillometric device (Connex ProBP 3400 Digital Blood Pressure Device, Welch Allyn UK Ltd.) 
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with 1 min rest between readings. The second and third readings were averaged to determine 
mean clinical blood pressure. 
Statistical analyses  
General data are presented as mean (95% confidence interval). Normal distribution of the 
sample was assessed using Shapiro-Wilk test. Differences between treatments (placebo vs 
CHX) were analysed using paired t-tests (data normally distributed) or Wilcoxon test (data 
non-normally distributed). Operational Taxonomic Units (OTUs) assigned to the major salivary 
bacterial phyla, and genera were analysed using the linear discriminant analysis (LDA) effect 
size (LEfSe) method37. The False Discovery Rate (FDR) was used at an alpha of 0.05 as 
previously indicated38. The Pearson correlation test was used to investigate relationship 
between relative oral bacterial abundance (OTUs %) and salivary markers. Bioinformatics 
analysis was performed using the OTUs_biom table generated in with MicrobiomeAnalysit39.    
Data Availability 
The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request. All data generated or analysed during this 
study are included in this published article. 
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Figure 1: Absolute abundance and Linear Discriminant Analysis (LDA) scores in the main bacterial phyla (A, B), genus (D, E) and family (F, G) 
after a 7-day treatment with placebo and chlorhexidine (CHX). Figure C shows the ratio between the two main phyla (Firmicutes:Bacteroidetes) 
following each treatment. Operational Taxonomic Units (OTUs) with an asterisk were statistically significant (False Discovery Rate > 0.05).  
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Figure 2: Shannon’s index representing alpha-diversity (A) and Bray-Curtis index representing beta-diversity (B) (each dot represents an 
individual sample and ellipsis represents the 95% confidence regions for group) after a 7-day treatment with placebo and chlorhexidine (CHX).  
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Figure 3: Saliva pH (A), saliva buffering capacity (B) and concentration of salivary lactate (C), 
glucose (D), nitrite (F), nitrate (G), as well as the nitrate-reducing capacity of oral bacteria (E) 
and concentration of plasma nitrite (H) and nitrate (I) after a 7-day treatment with placebo and 
chlorhexidine (CHX).   
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Figure 4: Moderate degree and significant Pearson correlations (r > 0.40; P < 0.05) found between abundance of oral bacteria (Operational 
Taxonomic Units [OTUs] %) at phylum level and salivary markers after the placebo and chlorhexidine treatment. In the placebo condition, 
abundance of Proteobacteria was negatively correlated to the oral nitrate-reducing capacity of bacteria (ONRC)  (A), and with lower levels of 
diastolic blood pressure (D). Abundance of Bacteroidetes was negatively associated with plasma nitrite (B), while abundance of Actinobacteria 
was positively correlated (E). Abundance of the phylum SR1 was positively associated with greater salivary pH. Following 7-day use of 
chlorhexidine, the abundance of Fusobacteria was correlated with greater concentration of glucose in saliva (F). Abundance of Actinobacteria 
was negatively correlated with saliva lactate (G), and abundance of Proteobacteria was also negatively correlated with saliva nitrite concentration 
(H).  
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Figure 5: Changes in systolic (SBP) and diastolic (DBP) blood pressure after 7-day use of placebo and chlorhexidine (CHX). 
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Table 1: Main characteristic of participants (mean ± SEM) 
Age (years) 26 ± 1 
Gender (F:M) 25:11 
Weight (kg) 65.4 ± 2.0 
Height (cm) 170.6 ± 1.9 
Systolic blood pressure 103.6 ± 1.2 
Diastolic blood pressure 62.8 ± 1.1 
Mean arterial blood pressure 76.4 ± 1.0 
 
 
